← Eichor
Study identifier: NCT06181812 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Pathogenic Variants in Genes Associated With Lung Adenocarcinoma

Condition: Lung Adenocarcinoma  ·  Sponsor: Oscar Gerardo Arrieta Rodríguez

PhaseN/A
Planned participants332
Who can joinAll sexes, 16 Years to 85 Years
Healthy volunteersNo

About this study

The goal of this observational study is to describe the prevalence of germ line-pathogenic variants in Mexican patients with lung adenocarcinoma. The main questions it aims to answer are: 1. What is the prevalence of pathogenic variants in genes associated with lung adenocarcinoma in Mexican patients younger than fifty? 2. Which clinical-pathological characteristics are associated with germ-line pathogenic variants in patients with lung adenocarcinoma? 3. How actionable somatic mutations are associated with germ line-pathogenic variants of patients with lung adenocarcinoma? Participants will be asked to sign an informed consent; after that, they will be instructed to donate 10 ml of peripheral blood by venipuncture in the morning and before the patient has taken morning medication and the first meal, following a period of 8-12 hr fasting.

This description comes directly from the study's public registry record.

Talk to the study team

Oscar G Arrieta Rodriguez, M.D., M.Sc.  ·  5556280400  ·  ogar@unam.mx

Always discuss trial participation with your own doctor first.

Locations (1)

Thoracic Oncology Unit and Personalized Medicine Laboratory, Instituto Nacional de CancerologíaMexico City, Mexico City, MexicoRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06181812